Latest news with #RoannaRuiz
Yahoo
07-07-2025
- Business
- Yahoo
Leerink Partners Reiterates a Buy Rating on Akebia Therapeutics (AKBA) With a $7 PT
Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the 13 Stocks Under $5 With High Upside Potential. On May 29, Leerink Partners analyst Roanna Ruiz maintained a Buy rating on Akebia Therapeutics, Inc. (NASDAQ:AKBA) and set a price target of $7.00. A biopharmaceutical team in a laboratory analyzing new compounds to develop therapeutics. The analyst reasoned that Akebia Therapeutics, Inc. (NASDAQ:AKBA) holds potential for growth, as discussions with key opinion leaders (KOLs) point towards considerable momentum for its product Vafseo in the dialysis market. Vafseo currently holds approval for the treatment of anemia in chronic kidney disease (CKD) dialysis patients, and is a notable revenue growth driver for the company, according to Ruiz. He further said that the non-dialysis CKD market shows another notable opportunity for the company, dependent on the success of the Phase 3 VALOR trial, anticipated to start in H2 2025. The analyst reasoned that the trial holds the potential to enhance the company's market potential and cause significant expansion of Vafseo's label. Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a biopharmaceutical company that develops and commercializes therapeutics for kidney diseases and renal and metabolic disorders. Its product pipeline includes Auryxia and Vadadustat. While we acknowledge the potential of AKBA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
24-06-2025
- Business
- Yahoo
Leerink Partners Maintains a Buy Rating on Ardelyx (ARDX) With a $10 PT
Ardelyx Inc. (NASDAQ:ARDX) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. On May 2, Leerink Partners analyst Roanna Ruiz reiterated a Buy rating on Ardelyx Inc. (NASDAQ:ARDX) and set a price target of $10.00. The optimistic rating was based on the company's solid commercial execution in spite of the challenges it faced in Q1. These included the loss of Medicare Part D coverage for Xphozah and the seasonal contraction in the IBS-C market. An aerial view of a pharmaceutical facility, showing the size and scale of the company's operations. The analyst reasoned that Ardelyx Inc. (NASDAQ:ARDX) maintained its guidance for Ibsrela, reflecting solid momentum with anticipated revenues for 2025 between the $240 to 250 million range. Another factor supporting the rating is the management's effective navigation of the Medicare Part D transition for Xphozah. Management also reaffirmed the long-term peak sales targets for Ardelyx Inc. (NASDAQ:ARDX), supporting them with growth drivers such as an expanded sales force and increased clinical conviction among prescribers. Ruiz further reasoned that the company's robust cash position justifies the buy rating, as it offers flexibility for continued business development opportunities and commercial investment. Ardelyx Inc. (NASDAQ:ARDX) develops and commercializes biopharmaceutical products. It is also involved in the development of an innovative platform that discovers new biological mechanisms and pathways to develop efficacious therapies, reducing the drug-drug interactions and side effects of traditional medicines. While we acknowledge the potential of ARDX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
31-05-2025
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: scPharmaceuticals (SCPH), 10x Genomics (TXG) and Kura Oncology (KURA)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on scPharmaceuticals (SCPH – Research Report), 10x Genomics (TXG – Research Report) and Kura Oncology (KURA – Research Report). Confident Investing Starts Here: scPharmaceuticals (SCPH) Leerink Partners analyst Roanna Ruiz maintained a Buy rating on scPharmaceuticals on May 14 and set a price target of $11.00. The company's shares closed last Friday at $3.22. According to Ruiz has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -16.1% and a 28.3% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Lexicon Pharmaceuticals, and Enanta Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for scPharmaceuticals with a $15.60 average price target, implying a 432.4% upside from current levels. In a report issued on May 12, Craig-Hallum also maintained a Buy rating on the stock. 10x Genomics (TXG) In a report issued on May 14, Puneet Souda from Leerink Partners maintained a Hold rating on 10x Genomics. The company's shares closed last Friday at $9.39, close to its 52-week low of $8.92. According to Souda has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -12.4% and a 29.8% success rate. Souda covers the Healthcare sector, focusing on stocks such as AbCellera Biologics, Castle Biosciences, and Twist Bioscience. Currently, the analyst consensus on 10x Genomics is a Moderate Buy with an average price target of $12.56, a 36.2% upside from current levels. In a report issued on May 9, TD Cowen also maintained a Hold rating on the stock with a $11.00 price target. Kura Oncology (KURA) In a report issued on May 14, Jonathan Chang from Leerink Partners reiterated a Buy rating on Kura Oncology, with a price target of $23.00. The company's shares closed last Friday at $6.02. According to Chang is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -13.0% and a 28.1% success rate. Chang covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Karyopharm Therapeutics, and Bicycle Therapeutics. Kura Oncology has an analyst consensus of Strong Buy, with a price target consensus of $22.60, a 279.2% upside from current levels. In a report issued on May 1, TD Cowen also maintained a Buy rating on the stock.
